Astrazeneca, Aifa specifies: preferable vaccine for under 55
AstraZeneca.
There is also the Aifa ok for the Italian-speaking vaccine
Covid, Ema: green light for AstraZeneca vaccine from the age of 18
Astrazeneca open to increase plants in the EU.
London: "Vaccines destined for us remain in GB"
Brussels publishes the contract with AstraZeneca.
Here is the text
Share
03 February 2021 The coronavirus vaccine that the University of Oxford has developed together with AstraZeneca has an efficacy of 76% in the three months following the first dose and could also have a "substantial effect" on coronavirus transmission: this is what is shown by a
preliminary
study
by the same university.
The initial results of this pre-print study (which therefore has not yet been examined by independent scientific experts) show that the preparation protects against covid-19 symptoms from day 22 after the first dose, when the immune system has already generated antibodies.
According to the research, with data collected up to 7 December 2020, vaccine efficacy increases from 54.9% with a six-week interval between both doses to 82.4% when the gap is twelve or more weeks. .
This finding would support - but must be further confirmed - the British government's choice to administer the two doses of the vaccine twelve weeks apart, a strategy that seeks to offer some protection against the virus to as many people as possible before completing and extending. immunity with a second dose.In addition, the study indicates that the preparation not only protects against the virus, but can also help reduce its transmission.
"Analysis of Pcr positive samples among the UK population suggests that the vaccine can have a substantial effect on virus transmission with a 67% reduction after the first dose," reads a University note.
The UK has already given the first dose of the coronavirus vaccine to 10 million people, and nearly 500,000 have already received the second.